Patents by Inventor Saurabh Srivastava

Saurabh Srivastava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11331324
    Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: May 17, 2022
    Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
  • Patent number: 11318145
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 3, 2022
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Publication number: 20220040196
    Abstract: The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 10, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Anil Jain, Saurabh Srivastava, Munish Dhiman
  • Publication number: 20210275539
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, TUSHARMOULI MUKHERJEE, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Patent number: 11112950
    Abstract: System and methods for personalizing an application include an application server for hosting an application that is executed on a wireless device, the server being configured to monitor usage of a user interface including an interaction between a user of the application and one or more user interface elements and present an updated user interface comprising one or more additional user-interface elements based on the usage.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 7, 2021
    Assignee: Conduent Business Services, LLC
    Inventors: Saurabh Srivastava, Simarjot Kaur, Tuhin Bhattacharya, Nupur Labh, James Macurak, Anuj Mahajan, Arun Rajkumar, Satish Prasad Rath, Narayanan Unny
  • Patent number: 11004006
    Abstract: Methods and systems for personalized trust recommendation based on a dynamic trust model. In an example embodiment, a trust framework can be derived from a set of use-case specific factors. Invasive data and non-invasive data can be collected from a user (or a group of users) based on activity data and profile data associated with the user. A dynamic trust profile can be created (or learned) based on the invasive data and the non-invasive data collected from the user. A recommended level of trustworthiness can be then provided to the user respect to a particular situation and/or entity (e.g. other users) within the trust framework based on the dynamic trust profile of the user and which is personalized for the user.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 11, 2021
    Assignee: Conduent Business Services, LLC
    Inventors: Jayati Bandyopadhyay, Nupur Labh, Simarjot Kaur, Arun Rajkumar, Saurabh Srivastava, Saurav Bhattacharya, Neha Singh
  • Patent number: 10946002
    Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 16, 2021
    Inventors: Kamal Surendrakumar Mehta, Dinesh Kumar, Saurabh Srivastava, Basudev Paul
  • Patent number: 10918630
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Publication number: 20200294148
    Abstract: Example analysis systems and methods are described. In one implementation, a system identifies a financial goal to be achieved and identifies financial account information associated with the financial goal. A plurality of insights are generated based on information from a plurality of data sources. A tool is implemented to generate at least one action based on the financial goal, the account information, and the insights. The system generates a recommendation based on the plurality of insights and the action, and automatically implements the recommendation to accomplish the financial goal.
    Type: Application
    Filed: March 11, 2020
    Publication date: September 17, 2020
    Inventors: Arjun Jayaram, Saurabh Srivastava, Mohammad Taha Abidi
  • Publication number: 20200253946
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Application
    Filed: December 13, 2019
    Publication date: August 13, 2020
    Applicant: Jubilant Generics Limited
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Publication number: 20200222420
    Abstract: The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: Jubilant Generics Limited
    Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
  • Publication number: 20200222421
    Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 16, 2020
    Applicant: Jubilant Generics Limited
    Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
  • Publication number: 20200085775
    Abstract: The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Inventors: Yogesh Bapurao PAWAR, Kailas KHOMANE, Saurabh SRIVASTAVA, Bijay Kumar PADHI, Rajeev Singh RAGHUVANSHI
  • Publication number: 20200074333
    Abstract: Methods and systems for personalized trust recommendation based on a dynamic trust model. In an example embodiment, a trust framework can be derived from a set of use-case specific factors. Invasive data and non-invasive data can be collected from a user (or a group of users) based on activity data and profile data associated with the user. A dynamic trust profile can be created (or learned) based on the invasive data and the non-invasive data collected from the user. A recommended level of trustworthiness can be then provided to the user respect to a particular situation and/or entity (e.g. other users) within the trust framework based on the dynamic trust profile of the user and which is personalized for the user.
    Type: Application
    Filed: August 30, 2018
    Publication date: March 5, 2020
    Inventors: Jayati Bandyopadhyay, Nupur Labh, Simarjot Kaur, Arun Rajkumar, Saurabh Srivastava, Saurav Bhattacharya, Neha Singh
  • Publication number: 20200074415
    Abstract: Example collateral optimization systems and methods are described. In one implementation, a collateral optimization system includes a data ingestion engine that receives information associated with a trade and a collateral optimization module configured to optimize collateral associated with the trade. The collateral can be optimized for yield maximization or cost minimization. An asset settlement engine moves assets between multiple counterparties associated with the trade.
    Type: Application
    Filed: June 18, 2019
    Publication date: March 5, 2020
    Inventors: Arjun Jayaram, Mohammad Taha Abidi, Saurabh Srivastava, Amish Asthana, James William Perry, Sumithra Sugavanam
  • Publication number: 20200046716
    Abstract: The present invention relates to a stable ready to use and powder for oral suspension dosage forms of Lamotrigine and its pharmaceutically acceptable salts and process of preparing such compositions. The liquid and powder for oral suspension dosage forms of Lamotrigine have been previously known only as extemporaneous preparations. Present invention relates to manufacture of liquid and powder for oral suspension dosage forms of Lamotrigine having improved physico-chemical properties with desired technical attributes. The prepared dosage forms are useful in patients having difficulties in swallowing tablets and provide physician with more options for dose titration.
    Type: Application
    Filed: February 2, 2018
    Publication date: February 13, 2020
    Inventors: Kamal Surendra Mehta, Dinesh Kumar, Saurabh Srivastava, Amit Jha, Rakesh K. Singh
  • Patent number: 10537562
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 21, 2020
    Assignee: Jubilant Generics Limited
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Patent number: 10517846
    Abstract: The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Yogesh Bapurao Pawar, Kailas Khomane, Saurabh Srivastava, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Publication number: 20190361579
    Abstract: System and methods for personalizing an application include an application server for hosting an application that is executed on a wireless device, the server being configured to monitor usage of a user interface including an interaction between a user of the application and one or more user interface elements and present an updated user interface comprising one or more additional user-interface elements based on the usage.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 28, 2019
    Applicant: Conduent Business Services, LLC
    Inventors: Saurabh SRIVASTAVA, Simarjot KAUR, Tuhin BHATTACHARYA, Nupur LABH, James MACURAK, Anuj MAHAJAN, Arun RAJKUMAR, Satish Prasad RATH, Narayanan UNNY
  • Publication number: 20190216788
    Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.
    Type: Application
    Filed: October 6, 2017
    Publication date: July 18, 2019
    Inventors: Kamal Surendrakumar Mehta, Dinesh Kumar, Saurabh Srivastava, Basudev Paul